Bausch Health Rises From Valeant's Simmering Ashes
Executive Summary
Valeant will change its name to Bausch Health beginning in July and get a new ticker symbol, BHC, as the new management team looks to leave the company's checkered past behind.
You may also be interested in...
Finance Watch: Olema IPO Raises $209m To Advance OPI-1250 For Breast Cancer
Olema launched this year’s 75th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
Consumer Health Brands Will Be Included In Bausch's Spin-Out Of Bausch Part Of Company
“The spin-off will establish two separate companies, a fully integrated, pure play, eye health company built on the iconic Bausch Health brand and a long history of innovation, and an international diversified pharmaceutical company with leading physicians in gastroenterology, dermatology, aesthetics, neurology and an international pharma business,” says CEO Joseph Papa.
Bausch To Spin-Out The Bausch Part Of Its Business
The company formerly known as Valeant, put together by a series of mergers, is ready to spin out the legacy Bausch + Lomb eyecare business that it used in its rebranding.